Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial

Am J Kidney Dis. 2023 Mar;81(3):373-376. doi: 10.1053/j.ajkd.2022.09.011. Epub 2022 Nov 1.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter

MeSH terms

  • Factor Xa Inhibitors
  • Humans
  • Nephrotic Syndrome*
  • Pyrazoles
  • Pyridones

Substances

  • apixaban
  • Pyrazoles
  • Pyridones
  • Factor Xa Inhibitors